1. Home
  2. MI vs ACRV Comparison

MI vs ACRV Comparison

Compare MI & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NFT Limited

MI

NFT Limited

HOLD

Current Price

$5.39

Market Cap

58.3M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.53

Market Cap

47.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MI
ACRV
Founded
2009
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.3M
47.6M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
MI
ACRV
Price
$5.39
$1.53
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$13.00
AVG Volume (30 Days)
12.9K
812.7K
Earning Date
01-01-0001
04-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
13.14
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$1.05
52 Week High
$6.70
$5.75

Technical Indicators

Market Signals
Indicator
MI
ACRV
Relative Strength Index (RSI) 61.63 41.45
Support Level $3.65 $1.51
Resistance Level $6.70 $2.47
Average True Range (ATR) 0.74 0.12
MACD 0.01 0.02
Stochastic Oscillator 51.30 22.47

Price Performance

Historical Comparison
MI
ACRV

About MI NFT Limited

NFT Ltd operates an online electronic platform for offering and trading artwork. Through its platform, the company allows artists/art dealers/owners to access a much bigger art trading market where artists can engage with a wide range of investors. Its platform also invests in high-end artwork accessible to ordinary people without financial resources. The company's trading platforms comprise the sale of calligraphies and paintings, jewelry, and precious stones. It generates revenue in the form of services in connection with the offering and trading of artwork on its system, consisting of listing fees, trading commissions, and management fees.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: